UroGen Pharma Ltd.(URGN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

UroGen Pharma Ltd. (URGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores URGN at 30.7/100 on a 32-signal composite quality model, placing it at rank #2,479 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), UroGen Pharma Ltd. reports quarterly revenue of $72.5M, net income of $-14.4M, free cash flow of $-33.1M. Top institutional holders of URGN by reported 13-F value include RTW INVESTMENTS, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. URGN trades on the Nasdaq exchange and files with the SEC under CIK 1668243. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate URGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UroGen Pharma Ltd. directly from SEC EDGAR.

AI Quality Score

30.7/100

AI Rank

#2,479

Revenue

$72.5M

Net Income

$-14.4M

Free Cash Flow

$-33.1M

URGN key financials by period

UroGen Pharma Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$109.8M$-153.5M-113.7%
FY 202410-K$90.4M$-126.9M-107.1%
FY 202310-K$82.7M$-102.2M-79.2%
FY 202210-K$64.4M$-109.8M-122.8%
FY 202110-K$48.0M$-110.8M-192.1%
FY 202010-K$11.8M$-128.5M—

Institutions holding URGN

Institutional investors reporting a position in UroGen Pharma Ltd. on SEC Form 13F.
InstitutionSharesValueReported
RTW INVESTMENTS4,543,895$167.2M2026-06-30
BlackRock3,201,461$117.8M2026-06-30
MORGAN STANLEY2,576,363$94.8M2026-06-30
Kynam Capital Management2,434,207$89.6M2026-06-30
LEUCADIA NATIONAL2,199,652$80.9M2026-06-30
SG Americas Securities2,052,906$75.5M2026-06-30
AMERICAN CENTURY COMPANIES1,685,719$62.0M2026-06-30
ACORN CAPITAL ADVISORS1,673,420$61.6M2026-06-30
Point72 Asset Management, L.P.1,525,549$56.1M2026-06-30
FRONTIER CAPITAL MANAGEMENT1,508,547$55.5M2026-06-30
SEC EDGAR: CIK 1668243 →
URGN

UroGen Pharma Ltd.

URGN
NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

30.7/100

Rank #2,479 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$72.46M

Net Income

Q2 2026
EDGAR

$-14.35M

EPS (Diluted)

Q2 2026
EDGAR

$-0.28

ROIC

Q2 2026
EDGAR

0.7%

Free Cash Flow

Q2 2026
EDGAR

$-33.07M

Top Institutional Holders

as of Q2 2026
$1.58B total
RTW INVESTMENTS, LP
$167.22M0.0%
BlackRock, Inc.
$117.81M+12.5%
MORGAN STANLEY
$94.81M+0.6%
Kynam Capital Management, LP
$89.58M+8.3%
LEUCADIA NATIONAL CORP
$80.95M0.0%
SG Americas Securities, LLC
$75.55M+23.8%
AMERICAN CENTURY COMPANIES INC
$62.03M+2.9%
ACORN CAPITAL ADVISORS, LLC
$61.58M0.0%
Point72 Asset Management, L.P.
$56.14MNew
FRONTIER CAPITAL MANAGEMENT CO LLC
$55.51M+14.8%

Financial Trends

Revenue & Net Income

Loading ratio trend…